If we focus on the correlation between SGLT2 inhibitors and cancers, both the SGLT2 inhibitors and malignancy precipitate euglycemic diabetic ketoacidosis while the interaction between SGLT2 inhibitors and cancer on euglycemic diabetic ketoacidosis risk remains unclear 25. Here, SLC5A2 is linked to type 2 diabetes mellitus.